Rival Research HQ’s Post

#Viral Vector Packaging Services Market: Growth Drivers and Key Players The Viral Vector Packaging Services market is growing due to the increasing demand for gene therapies and vaccines. These services play a crucial role in the production of viral vectors used in genetic treatments, enabling the safe and efficient delivery of therapeutic genes. Advancements in biotechnology and regulatory support for gene-based treatments are fueling market growth. visitor more Visit us- https://lnkd.in/eaVfsrNQ players include: Lonza ViroCell Biologics Sartorius Catalent Pharma Solutions Pfizer Novasep BASF Cellgene Ltd Grifols BIOVECTRA GSK Merck Group AbbVie AstraZeneca Amgen Biogen Bayer Teva Pharmaceuticals Sanofi Regeneron Moderna The Janssen Pharmaceutical Companies of Johnson & Johnson #ViralVector #GeneTherapy #BiotechServices #VaccineDevelopment #MarketGrowth

𝐌𝐚𝐫𝐤𝐞𝐭 𝐜𝐚𝐩 𝐯𝐬 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 The year is almost over, and the pharma companies have released Q3 reports. Given the enormous market caps, the revenues (still in USD billions) look relatively 'modest'. With Eli Lilly and Company and Novo Nordisk on the top, the industry clearly shows the trend towards GLP-1 agonists and obesity and diabetes treatments. Within the ranking, there is space for 'niche' innovations in pharma, such as CSL with their Hemgenix or Vertex Pharmaceuticals with Casgevy, developed with CRISPR Therapeutics (go go gene therapies!). Here is the list of the top companies by market cap: 1. Eli Lilly and Company - $715.3B 2. Novo Nordisk - $467.5B 3. Johnson & Johnson - $373.2B 4. AbbVie - $323.3B 5. Merck - $257.1B 6. Roche - $233.0B 7. Novartis - $211.5B 8. AstraZeneca - $209.7B 9. Amgen - $152.1B 10. Pfizer - $148.5B 11. Sanofi - $121.6B 12. Vertex Pharmaceuticals - $120.6B 13. Bristol Myers Squibb - $120.1B 14. Gilead Sciences - $115.4B 15. CSL - $90.1B #pharma #biotech #businessinsights Source: companiesmarketcap ----------

🚀 Weekly Roundup - PHARMA  – 5 August 2024 🚀 Stay in the lead with last week's top pharmaceutical industry highlights! 📈💊 Click here to read more ➡ https://lnkd.in/eDV8dXVv    🔊 Pfizer Receives Conditional Authorization from EC for DURVEQTIX Gene Therapy in Hemophilia B  🔊 Luye Pharma's Extended-Release Injectable Suspension ERZOFRI for Schizophrenia and Schizoaffective Disorder Receives FDA Approval  🔊 Boehringer Ingelheim to Acquire Nerio Therapeutics for Up to $1.3B in a Strategic Move Towards Immuno-Oncology  🔊 Japan’s Otsuka Pharma to Buy Jnana Therapeutics for Up to $1.1B  🔊 Prelude Forms New Partnership with Merck to Evaluate PRT3789 for Cancers Associated with the SMARCA2 and SMARCA4 Genes    #Pfizer #DURVEQTIX #LuyePharma #ERZOFRI #BoehringerIngelheim #NerioTherapeutics #OtsukaPharma #JnanaTherapeutics #Prelude #Merck #PRT3789 #PharmaNews #Biotech #Pharma #Healthcare #ClinicalTrials 

Eder Therapeutics and xcube.bio have announced a strategic cooperation to facilitate the market entry and commercialization of biotech assets in Canada and Europe. The two companies will coordinate their offerings to biopharma innovators in their respective regions and leverage the numerous synergies that exist between the healthcare systems of Europe and Canada. The collaboration will specifically focus on product profiling, regulatory processes, Health Technology Assessment (HTA), and medical communication, and commercialization - ultimately benefiting patients and biopharma partners.   "Eder Therapeutics is thrilled to combine its unique depth in the Canadian market with the breadth of a European platform like xcube.bio. This partnership will enhance access to innovative treatments for Canadian patients, which is our ultimate goal," said Jared Rhines, CEO of Eder Therapeutics.   Pierre-Henri Belin, CEO of xcube.bio, stated, "xcube.bio, a European market-entry specialist, has found a valued like-minded partner in Eder Therapeutics. We look forward to expanding this cooperation to accelerate patient access and provide added value to our biopharma partners."   An initial phase of expert cooperation will begin with Eder Therapeutics' investigational gene therapy for Lipoprotein Lipase Deficiency. #biopharma #partnering #commercialization

🔥 Hot of the press - Zymewire's Q2 Biopharma Industry Recap is live! 📊 Curious about what's driving the industry forward this quarter? Our latest blog reveals key statistics and trends from Q2 2024 that every service provider needs to know. What's inside? 🌏 Upcoming Clinical Trials by Region 💊 New FDA drug approvals 💸 Funding patterns by company size and therapeutic focus 🧬 Cell & Gene Therapy Plans If your business revolves around changes in the biopharma sector, these insights are crucial for staying ahead in a competitive market. Dive into the full blog below to get the details and make smarter data-driven business decisions. https://lnkd.in/eny44pkr #Biopharma #ClinicalTrials #FDAApprovals #Funding #Q2Insights

I am very excited to share my latest article 2024 New Drug Modalities Report, co-authored by me and my BCG colleagues Brian Bush, Mike Brochu, Gian King, PharmD. It's been an exciting year since our 2023 report. New modalities represent $168 billion in projected pipeline value in 2024, up 14% from 2024. ADCs and GLP-1s have had breakout success. Gene therapies for rare diseases, microbiomes, and oncolytic virus saw their first US approvals in the past year. CAR-T and mRNA continue to mature and broaden their applications beyond the initial therapeutics. Large Biopharmas have spent nearly $200B since 2022 in deal making in new modalities. The next few years are likely to be exceptionally competitive for new modalities. Not all new modalities can be winners. The success of each new modality will hinge on its unique value proposition and its capacity to enhance the standard of care. As you review the insights, please reach out with any feedback and perspective. Always excited to bounce ideas with fellow 'new modalities enthusiasts'! https://lnkd.in/g6rYim6s

Gene Therapy Market worth $23.9 billion by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/gRQZAkZU The global #genetherapy market was valued at $9.0 billion in 2023 and is projected to reach $23.9 billion by 2028, with a robust CAGR of 21.4% during the forecast period (2023-2028). Novartis Biogen Gilead Sciences. Bristol Myers Squibb Alnylam Pharmaceuticals Sarepta Therapeutics Amgen. Orchard Therapeutics F. Hoffmann-La Roche Ltd Jazz Pharmaceuticals uniQure Johnson & Johnson bluebird bio. BioMarin Pharmaceutical Inc. Krystal Biotech, Inc. Shanghai Sunway Biotech Co. Ltd. Vertex Pharmaceuticals Pfizer. Sangamo Therapeutics, Inc. REGENXBIO Inc. Ultragenyx MeiraGTx ANGES

𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀 𝘄𝗶𝘁𝗵 𝗛𝗮𝘆𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝘁𝗼 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝗹𝗼𝗻𝗴 𝗻𝗼𝗻𝗰𝗼𝗱𝗶𝗻𝗴 𝗥𝗡𝗔-𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗱𝗿𝘂𝗴 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀 𝗳𝗼𝗿 𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗖𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗢𝗯𝗲𝘀𝗶𝘁𝘆. Eli Lilly is partnering with Haya Therapeutics to discover new drug targets for chronic metabolic conditions and obesity. Founded in 2017, Haya has homed in on long noncoding RNAs (lncRNAs) as potential targets to treat diseases. These RNA molecules are not translated into proteins but, rather, interact with and regulate biological processes. Haya’s innovative platform focuses on identifying tissue- and disease-specific lncRNAs to develop RNA-targeting therapies. #obesity #metabolism #metabolicdisease #therapy #RNA #innovation #biotech #pharmaceuticalcompany #medicine

Australia’s first RNA Blueprint, released this week by the Albanese Government, recognises the significant contribution our nation makes to the global pharmaceutical industry through research and development.   The focus on building and strengthening international partnerships in the Blueprint is important as the global supply chain is dependent on cooperation and collaboration.    It is pleasing to see the Cell & Gene Catalyst, a joint venture between AusBiotech and Medicines Australia, is recognised as a potential strategic partner to bring the ecosystem together.   The Catalyst has been established to accelerate the development, manufacture and commercialisation of cell and gene therapies, including RNA, to foster a prosperous cell and gene industry in Australia.   Alongside efforts to strengthen the local research and development of new medicines, Medicines Australia calls on the Government to commit to the bold reforms needed to ensure Australians can access the best medicines available, when they need them, through our Pharmaceutical Benefits Scheme.  Ed Husic MP #MarkButlerMP #RNA AusBiotech Dr Marguerite Evans-Galea AM Elizabeth de Somer #AustraliasCellandGeneCatalyst